<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03406416</url>
  </required_header>
  <id_info>
    <org_study_id>BVT_001</org_study_id>
    <nct_id>NCT03406416</nct_id>
  </id_info>
  <brief_title>Study of a Suprachoroidal Retinal Prosthesis</brief_title>
  <official_title>Evaluation of a Suprachoroidal Retinal Prosthesis: A 44 Channel Fully Implantable Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mobius Medical Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bionic Vision Technologies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Eye Research Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bionics Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Data 61 CSIRO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Australian National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mobius Medical Pty Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a proof of principal, to evaluate a safety and efficacy of a prototype&#xD;
      suprachoroidal retinal implant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinal visual prostheses are currently in early development as an intervention to improve&#xD;
      functional vision in people who have become blind from retinal degenerative eye disease. This&#xD;
      study follows on from an initial proof of concept study (n=3) between 2012 and 2014, and will&#xD;
      test a second-generation retinal prosthesis device, which has the ability to be used outside&#xD;
      of the laboratory environment (i.e. is fully implantable).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2018</start_date>
  <completion_date type="Actual">December 18, 2020</completion_date>
  <primary_completion_date type="Actual">December 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of device related serious adverse events (SAEs)</measure>
    <time_frame>2 years</time_frame>
    <description>The safety of the surgical implantation assessed by the number and severity of serious adverse events (SAEs) compared to other retinal prosthesis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy - visual response</measure>
    <time_frame>2 years</time_frame>
    <description>The ability to generate a visual response accessed via repeatable threshold measurements of visual perception.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Function and Functional Vision</measure>
    <time_frame>2 years</time_frame>
    <description>Visual function and Functional Vision will be scored from performance on a range of acuity, orientation and mobility, and activities of daily living tasks. Outcome measures include:&#xD;
Grating visual acuity: record the grating acuity level and average response time.&#xD;
Square localization: response error and response time is measured.&#xD;
Motion detection: response error and response time is measured.&#xD;
Table top task: locate and identify objects on a table. Accuracy rates and response times will be recorded.&#xD;
Doorway detection task: to find doorway target. Task time and accuracy of door touch will be recorded.&#xD;
Obstacle avoidance task: task time and number of collisions is recorded.&#xD;
Functional Low Vision Observer Rated Assessment (FLORA): this assessment tool Is used to evaluate participant functional vision and mobility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - IVI - very low vision validated questionnaire</measure>
    <time_frame>2 years</time_frame>
    <description>Quality of life will be assessed via survey and self-report. The Functional Low Vision Observer Assessment (FLORA) is a questionnaire that will be used to measure participants changes in participant daily living experiences.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <condition>Choroideremia</condition>
  <arm_group>
    <arm_group_label>Suprachoroidal retinal prosthesis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prototype wide view suprachoroidal retinal prosthesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>44Ch Bionic Eye Device</intervention_name>
    <description>Prototype wide view suprachoroidal retinal prosthesis</description>
    <arm_group_label>Suprachoroidal retinal prosthesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
          -  Either gender&#xD;
&#xD;
          -  A confirmed history of outer retinal degenerative disease such as retinitis pigmentosa&#xD;
             or choroideremia&#xD;
&#xD;
          -  Remaining visual acuity of bare light perception or less in both eyes&#xD;
&#xD;
          -  Functional inner retina (ganglion cells and optic nerve), as shown by the ability to&#xD;
             perceive light and/or a measurable corneal electrically evoked visual response&#xD;
&#xD;
          -  A history of at least 10 years of useful form vision in the worse seeing eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Optic nerve disease (history of glaucoma of More than 1 month, or history of any other&#xD;
             optic neuropathy)&#xD;
&#xD;
          -  Diseases of the inner retina including, but not limited to, central retinal artery or&#xD;
             vein occlusion (CRAO, CRVO), end stage diabetic retinopathy, retinal detachment,&#xD;
             traumatic retinal damage, infectious retinal disease, inflammatory retinal disease.&#xD;
&#xD;
          -  Inability to visualise the retina due to corneal or other ocular media opacities&#xD;
             (corneal degenerations, dense cataracts, trauma, lid malpositions)&#xD;
&#xD;
          -  Any ocular condition that predisposes the participant to rubbing their eyes&#xD;
&#xD;
          -  Cognitive deficiencies, including dementia or progressive neurological disease&#xD;
&#xD;
          -  Psychiatric disorders, including depression, as diagnosed by a qualified psychologist&#xD;
&#xD;
          -  Deafness or significant hearing loss&#xD;
&#xD;
          -  Inability to speak or understand English&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Presence of a cochlear implant&#xD;
&#xD;
          -  Participant enrolled in another investigational drug or device trial for the treatment&#xD;
             of their ocular condition&#xD;
&#xD;
          -  Poor general health, which would exclude them from obtaining a general anaesthetic&#xD;
&#xD;
          -  Unrealistic expectations of the investigational device to provide functional vision&#xD;
&#xD;
          -  Poorly controlled diabetes&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Unsuitable level of regular nystagmus (which would prevent ocular images from being&#xD;
             obtained)&#xD;
&#xD;
          -  Anyone with medical devices (implanted or carried) that could cause serious health&#xD;
             problems if compromised by electro-magnetic interference&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Penelope Allen, FRACO, FRACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Eye Research Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Eye Research Australia</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Ayton LN, Blamey PJ, Guymer RH, Luu CD, Nayagam DA, Sinclair NC, Shivdasani MN, Yeoh J, McCombe MF, Briggs RJ, Opie NL, Villalobos J, Dimitrov PN, Varsamidis M, Petoe MA, McCarthy CD, Walker JG, Barnes N, Burkitt AN, Williams CE, Shepherd RK, Allen PJ; Bionic Vision Australia Research Consortium. First-in-human trial of a novel suprachoroidal retinal prosthesis. PLoS One. 2014 Dec 18;9(12):e115239. doi: 10.1371/journal.pone.0115239. eCollection 2014.</citation>
    <PMID>25521292</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 26, 2017</study_first_submitted>
  <study_first_submitted_qc>January 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Choroideremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

